Literature DB >> 11076091

Abnormal TGFbeta levels in the amniotic fluid of Down syndrome pregnancies.

S J Bromage1, A K Lang, I Atkinson, R F Searle.   

Abstract

PROBLEM: The status of cytokines in amniotic fluid (AF) from chromosomally abnormal pregnancy is largely undefined. TGFbeta plays a key role in fetal growth and differentiation and is responsible for the immunoregulatory activity of AF in normal pregnancy, but its status in Down syndrome (DS) pregnancies is unknown. In addition we investigated the IL-2 status of AF from DS pregnancies. METHOD OF STUDY: Midtrimester AF from chromosomally normal (n = 25) and abnormal pregnancies with DS (n = 15) were assayed for bioactive and latent TGFbeta levels using the mink lung epithelial cell growth inhibition bioassay and for IL-2 activity by the CTLL-2 cell proliferation bioassay and by ELISA.
RESULTS: Levels of bioactive TGFbeta (mean 4.6+/-0.6 U/mL) were significantly increased in DS AF compared with the normal samples (mean 2.8+/-0.3 U/mL, P<0.003) but latent TGFbeta levels did not differ between DS and normal groups. In addition DS AFs showed reduced IL-2 like bioactivity compared with normal samples (P = 0.0006) but IL-2 immunoactivity was undetectable in DS and normal AFs by ELISA.
CONCLUSIONS: DS AFs display increased TGFbeta activity and lacked IL-2 immunoactivity. The reduced ability of DS AFs to stimulate CTLL-2 cell proliferation is unrelated to the IL-2 status of AF. Altered TGFbeta levels may prove useful as an additional biochemical index for the detection of DS pregnancies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076091     DOI: 10.1111/j.8755-8920.2000.440403.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  5 in total

1.  Maternal plasma and amniotic fluid chemokines screening in fetal Down syndrome.

Authors:  Piotr Laudanski; Monika Zbucka-Kretowska; Karol Charkiewicz; Slawomir Wolczynski; Daniela Wojcik; Radoslaw Charkiewicz
Journal:  Mediators Inflamm       Date:  2014-11-16       Impact factor: 4.711

2.  Differentially expressed microRNAs in maternal plasma for the noninvasive prenatal diagnosis of Down syndrome (trisomy 21).

Authors:  Julian Kamhieh-Milz; Reham Fadl Hassan Moftah; Gürkan Bal; Matthias Futschik; Viktor Sterzer; Omid Khorramshahi; Martin Burow; Gundula Thiel; Annegret Stuke-Sontheimer; Rabih Chaoui; Sundrela Kamhieh-Milz; Abdulgabar Salama
Journal:  Biomed Res Int       Date:  2014-11-12       Impact factor: 3.411

Review 3.  Control of human trophoblast function.

Authors:  Laura Lunghi; Maria E Ferretti; Silvia Medici; Carla Biondi; Fortunato Vesce
Journal:  Reprod Biol Endocrinol       Date:  2007-02-08       Impact factor: 5.211

4.  Maternal plasma angiogenic and inflammatory factor profiling in foetal Down syndrome.

Authors:  Monika Zbucka-Kretowska; Karol Charkiewicz; Joanna Goscik; Slawomir Wolczynski; Piotr Laudanski
Journal:  PLoS One       Date:  2017-12-15       Impact factor: 3.240

5.  Differential microRNA expression profile in blood of children with Down syndrome suggests a role in immunological dysfunction.

Authors:  Joice Matos Biselli; Bruna Lancia Zampieri; Patrícia Matos Biselli-Chicote; Jorge Estefano Santana de Souza; Matheus Carvalho Bürger; Wilson Araújo da Silva; Eny Maria Goloni-Bertollo; Érika Cristina Pavarino
Journal:  Hum Cell       Date:  2022-01-20       Impact factor: 4.374

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.